Literature DB >> 12549658

Elderly patients on chronic hemodialysis: effect of the secondary hyperparathyroidism on the hemoglobin level.

Pedro L Neves1, Julio Triviño, Francisco Casaubon, Paulo Romão, Patricia Mendes, Isilda Bexiga, Isabel Pinto, Viriato Santos, Idalécio Bernardo.   

Abstract

In patients on chronic hemodialysis (CHD) hyperparathyroidism (HPTH) is associated with anemia and resistance to erythropoietin (EPO). This study included 86 CHD elderly pts (mean age 74.8 y, mean time on CHD = 50.5 mos); they were divided into two groups: I (n = 31) - PTH > 250 pg/mL and II (n = 55) - PTH < 250 pg/mL. All these patients had been on CHD for > 6 mos. No differences were found between groups in respect to age, sex distribution and time on CHD. The levels of creatinine, BUN, Ca, Al, Fe, albumin and ferritin were similar. Group I had a higher P level (5.4 vs 4.3 mg/dL, p = 0.001) and Ca x P (53.5 vs 43.7, p = 0.009). Also the Hct (31 vs 33.5%, p = 0.008) and the Hb (10.4 vs 11.2 g/dL, p = 0.009) values were lower in Group I. The EPO dose (88 vs 85 U/kg/week, p = ns) was similar in the two groups. Our data showed that elderly patients with HPTH have lower Hct and Hb levels than do younger patients on a similar EPO dose. We believe these patients will need a more aggressive therapy with calcitriol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12549658     DOI: 10.1023/a:1021380609993

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  Report on management of renal failure in Europe, XXII, 1991.

Authors:  A E Raine; R Margreiter; F P Brunner; J H Ehrich; W Geerlings; P Landais; C Loirat; N P Mallick; N H Selwood; G Tufveson
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

Review 2.  R-HuEPO hyporesponsiveness--who and why?

Authors:  T B Drüeke
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

Review 3.  Is there a role for adjuvant therapy in patients being treated with epoetin?

Authors:  W H Hörl
Journal:  Nephrol Dial Transplant       Date:  1999       Impact factor: 5.992

4.  Health care policies/economics of the geriatric renal population.

Authors:  P W Eggers
Journal:  Am J Kidney Dis       Date:  1990-10       Impact factor: 8.860

5.  European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure.

Authors: 
Journal:  Nephrol Dial Transplant       Date:  1999       Impact factor: 5.992

6.  R-HuEPO hyporesponsiveness--who and why?

Authors:  B Danielson
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

Review 7.  Historical review on the use of recombinant human erythropoietin in chronic renal failure.

Authors:  C G Winearls
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

8.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

9.  National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group.

Authors:  N W Levin; J M Lazarus; A R Nissenson
Journal:  Am J Kidney Dis       Date:  1993-08       Impact factor: 8.860

10.  Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.

Authors:  D S Rao; M S Shih; R Mohini
Journal:  N Engl J Med       Date:  1993-01-21       Impact factor: 91.245

View more
  1 in total

Review 1.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.